Diecidue Robert J, LaNoue Marianna D, Manning Erika L, Huntley Colin T, Harrington Joseph D
Professor and Chair, Department of Oral and Maxillofacial Surgery, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA.
Professor, School of Nursing, Vanderbilt University, Nashville, TN.
J Oral Maxillofac Surg. 2024 Dec;82(12):1537-1548. doi: 10.1016/j.joms.2024.07.015. Epub 2024 Aug 7.
Continuous positive airway pressure (CPAP), mandibular advancement device (MAD), upper airway stimulation (UAS), and maxillomandibular advancement (MMA) are techniques to reduce apnea hypopnea index (AHI) in obstructive sleep apnea (OSA) patients. Current literature does not include a direct comparison of the 4 methods.
The purpose of this study is to measure and compare the efficacy of 4 common OSA treatments: CPAP, MAD, UAS, MMA.
STUDY DESIGN, SETTING, SAMPLE: This retrospective cohort study examines data from 119 patients treated at Thomas Jefferson University Hospital in Philadelphia receiving CPAP, MAD, UAS, or MMA between January 2018 and December 2020. Patients were excluded for significant medical comorbidities, body mass index ≥45, cognitive limitations, central/mixed apnea history, or pregnancy.
The primary predictor variable was type of OSA intervention: CPAP, MAD, UAS, MMA. Treatments were assigned by treating physicians per their presenting OSA severity.
The primary outcome variable was efficacy defined as the therapeutic response to treatment measured using mean disease alleviation, a calculated variable (percentage) which employs post-treatment AHI adjusted by compliance (a measure of a patient's device use). Secondary therapeutic measures included remaining AHI and patient-reported outcome measures: Epworth Sleepiness Scale, Sleep Apnea Quality of Life Index, Patient-reported Apnea Questionnaire.
Demographic covariates included age, sex, height, weight, socioeconomic status, level of education, neck size, race, and body mass index. Clinical covariates included pretreatment AHI, AHI change, O2 nadir, adjusted compliance, and compliance.
Multivariate statistics were computed with alpha level of 0.05, including a regression with the primary outcome variables, treatment variables, and potential covariates.
The sample included 119 subjects (mean age = 56.12, standard deviation [SD] = 5.81) with males at n = 72 (60%). MMA demonstrated greatest mean disease alleviation (M = 36.08, SD = 28.56), compared to UAS (M = 22.88, SD = 3.16), MAD (M = 6.80, SD = 8.13), and CPAP (M = 5.00, SD = 14.80), analysis of variance: P < .001.
Both surgical treatments displayed significantly greater effectiveness than CPAP and MAD, suggesting that offering surgical alternatives sooner, particularly to those with severe OSA, may be logical in formulating more effective treatment guidelines.
持续气道正压通气(CPAP)、下颌前移装置(MAD)、上气道刺激(UAS)和上颌下颌前移术(MMA)是降低阻塞性睡眠呼吸暂停(OSA)患者呼吸暂停低通气指数(AHI)的技术。当前文献中未对这四种方法进行直接比较。
本研究的目的是测量和比较四种常见的OSA治疗方法的疗效:CPAP、MAD、UAS、MMA。
研究设计、设置、样本:这项回顾性队列研究分析了2018年1月至2020年12月期间在费城托马斯·杰斐逊大学医院接受CPAP、MAD、UAS或MMA治疗的119例患者的数据。患有严重内科合并症、体重指数≥45、认知功能受限、有中枢性/混合性呼吸暂停病史或怀孕的患者被排除在外。
主要预测变量是OSA干预类型:CPAP、MAD、UAS、MMA。治疗由主治医生根据患者呈现的OSA严重程度进行分配。
主要结局变量是疗效,定义为使用平均疾病缓解程度来衡量的治疗反应,这是一个计算得出的变量(百分比),采用经依从性调整后的治疗后AHI(衡量患者设备使用情况的指标)。次要治疗指标包括剩余AHI和患者报告的结局指标:爱泼华嗜睡量表、睡眠呼吸暂停生活质量指数、患者报告的呼吸暂停问卷。
人口统计学协变量包括年龄、性别、身高、体重、社会经济地位、教育程度、颈部尺寸、种族和体重指数。临床协变量包括治疗前AHI、AHI变化、最低血氧饱和度、调整后的依从性和依从性。
计算多变量统计量,α水平为0.05,包括对主要结局变量、治疗变量和潜在协变量进行回归分析。
样本包括119名受试者(平均年龄=56.12,标准差[SD]=5.81),其中男性72名(60%)。与UAS(M=22.88,SD=3.16)、MAD(M=6.80,SD=8.13)和CPAP(M=5.00,SD=14.80)相比,MMA显示出最大的平均疾病缓解程度(M=36.08,SD=28.56),方差分析:P<.001。
两种手术治疗方法均显示出比CPAP和MAD显著更高的有效性,这表明在制定更有效的治疗指南时,尽早提供手术替代方案,尤其是对那些患有严重OSA的患者,可能是合理的。